Latest filing published 29 Jun 2021 for Fulcrum Therapeutics, Inc., €17k.
Filing timeline
BuySaleInsider track record
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
No signal scores available.
Peter G. Thomson: trading record in brief
Peter G. Thomson, listed as senior executive, appears in our data through filings on Fulcrum Therapeutics, Inc. shares, published by SEC (Form 4). Between 23 January 2020 and 28 June 2021, the trades on record add up to 10 filings.
Both buying and selling appear: 1 purchase worth €17k, against 8 sales worth €403k. On balance, insiders were net sellers of €386k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 1 option exercise. In 2021 alone, the filings show 1 purchase and 2 sales.
The newest entry dates from 29 June 2021: an open-market purchase of €17k, in Fulcrum Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Peter G. Thomson
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 2,300 shares@ US$9.00100.0% of flowCommon StockSEC:0000899243-21-026555:0Canonical exit: 26 Sept 2021 (T+90)
1 of 1 declaration
